Multiple Sclerosis CD19+ B Cells

About Multiple Sclerosis CD19+ B Cells

Multiple Sclerosis CD19+ B Cells for Neuroimmunology and Autoimmune Research

Multiple Sclerosis CD19+ B Cells are purified from the peripheral blood of IRB-consented adult donors with a clinically confirmed diagnosis of multiple sclerosis (MS), processed within 24 hours of collection and cryopreserved in CryoStor CS10 media. MS is an autoimmune, inflammatory demyelinating disease of the central nervous system, and B cells are now understood to be a central driver of relapsing disease rather than a bystander population.

Why CD19+ B Cells in Multiple Sclerosis

• The case for B cells in MS was established therapeutically: B-cell depleting anti-CD20 antibodies markedly reduce relapse rate and new lesion formation, and they do so within weeks, faster than antibody titres could plausibly fall. That argues for antibody-independent B-cell functions as the operative mechanism.
• Those functions include antigen presentation to CD4 T cells and secretion of pro-inflammatory cytokines such as GM-CSF, IL-6, TNF and lymphotoxin, alongside impaired regulatory (IL-10-producing) B-cell activity. Isolated CD19+ B cells let these outputs be measured directly rather than inferred from bulk PBMC.
• Unlike NMOSD or MOGAD, MS has no single established pathogenic autoantibody. What is well documented is intrathecal immunoglobulin synthesis, seen as cerebrospinal fluid oligoclonal bands and an elevated IgG index, together with meningeal B-cell aggregates in progressive disease. Peripheral CD19+ B cells provide the accessible compartment for repertoire and clonality studies that connect to that intrathecal activity.
• Memory B cells appear to be the key pathogenic reservoir, and CD19 selection captures a broader B-lineage range than CD20 selection, including plasmablasts that CD20-directed therapies largely spare, which matters when studying residual disease activity under treatment.
• Epstein-Barr virus infection has a strong and consistent epidemiological association with MS risk, and B cells are the natural host cell for EBV latency, making isolated MS B cells the relevant substrate for research into that relationship.
• Cryopreserved, purified B cells support BCR repertoire sequencing, in vitro activation and differentiation, antigen-presentation co-culture assays and depletion or signalling-inhibitor pharmacology in patient-derived cells.

Donor Stratification Available

• MS subtype: relapsing-remitting, secondary progressive, or primary progressive where documented
• Disability and disease duration, including EDSS where documented
• Clinical state: recent relapse versus clinical remission
• Treatment status: treatment-naive, or on interferon beta, glatiramer acetate, dimethyl fumarate, S1P modulator, natalizumab, anti-CD20 therapy (note that B-cell yields are reduced or absent in recently depleted donors), or cladribine
• CSF findings where documented, including oligoclonal band status and IgG index; MRI lesion burden where documented
• Matched healthy control CD19+ B cells available, and B cells from other autoimmune donors for comparison

Product Features

• Research Use Only (RUO), CD19+ B cells
• Isolated from multiple sclerosis donors with confirmed clinical diagnosis
• High purity and viability; values reported per lot
• Cryopreserved using CryoStor CS10 media
• Processed within 24 hours of collection
• Standard and custom aliquot sizes; matched autologous PBMC and plasma available on request
• IRB-approved protocols and HIPAA-compliant handling

De-identified Donor Data

• Confirmed diagnosis of multiple sclerosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Medication and clinical history available
• MS subtype and disease-specific detail available on request

Applications

• B-cell immunophenotyping across naive, memory, double-negative and plasmablast compartments
• B-cell cytokine output profiling, including GM-CSF, IL-6 and IL-10
• Antigen presentation and B-cell/T-cell co-culture assays
• BCR repertoire sequencing and clonality analysis
• B-cell receptor signalling and BTK inhibitor pharmacology
• Anti-CD20 and B-cell depletion mechanism-of-action research
• EBV latency and virus-host interaction studies in patient B cells
• Biomarker discovery and therapeutic target validation in neuroimmunology

Other Multiple Sclerosis Specimen Types

• Multiple Sclerosis PBMC
• Multiple Sclerosis Leukopak
• Multiple Sclerosis Serum
• Multiple Sclerosis Plasma
• Multiple Sclerosis Whole Blood
• Multiple Sclerosis Cerebrospinal Fluid
• Multiple Sclerosis CD4+ T Cells
• Multiple Sclerosis CD8+ T Cells

Compliance and Quality Assurance

• IRB-approved collections with 21 CFR Part 11-compliant e-consent
• Standardized processing and cryopreservation protocols
• HIPAA-compliant donor data protection

Ordering & Customization

Multiple Sclerosis CD19+ B Cells are available in standard or custom aliquot sizes. For pricing, current availability, or a quote on a stratified donor cohort, contact learnmore@sanguinebio.com; email us as well for international shipping, documentation or regulatory support. To browse other disease states and the source material these cells are isolated from, visit our human CD19+ B cells and human PBMC pages.